目的 探討復(fù)方丹參滴丸聯(lián)合注射用重組人尿激酶原治療急性ST段抬高型心肌梗死的臨床療效。方法 選取2015年6月-2017年6月河南大學(xué)第一附屬醫(yī)院收治的急性ST段抬高型心肌梗死患者120例為研究對象，將所有患者隨機分為對照組和治療組，每組各60例。對照組給予注射用重組人尿激酶原，50 mg/次，先將20 mg加入到生理鹽水10 mL，3 min內(nèi)靜脈推注完畢，然后30 mg加入到生理鹽水90 mL，30 min內(nèi)靜脈滴注完畢。治療組在對照組治療的基礎(chǔ)上口服復(fù)方丹參滴丸，10丸/次，3次/d。兩組患者均持續(xù)治療15 d。觀察兩組的臨床療效，比較兩組的血管再通率和左心功能。結(jié)果 治療后，對照組和治療組的總有效率分別為81.66%、96.67%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，對照組血管再通率為83.33%；治療組血管再通率為93.33%，兩組血管再通率比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組左心室舒張期末內(nèi)徑（LVEDD）、左心室射血分數(shù)（LVEF）均顯著升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組左心功能指標(biāo)明顯高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 復(fù)方丹參滴丸聯(lián)合注射用重組人尿激酶原治療急性ST段抬高型心肌梗死具有較好的臨床療效，顯著提高血管再通率，改善左心功能，安全性較好，具有一定臨床推廣應(yīng)用價值。

Objective To investigate the effects of Compound Danshen Dripping Pills combined with Reocmbinant Human Prourokinase for injection in treatment of acute ST segment elevation myocardial infarction. Methods Patients (120 cases) with acute ST segment elevation myocardial infarction in the First Affiliated Hospital of Henan University from June 2015 to June 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were given Reocmbinant Human Prourokinase for injection, 50 mg/time, first 20 mg added into normal saline 10 mL, intravenous injection within 3 min, then 30 mg added into normal saline 90 mL, intravenous drip within 30 min. Patients in the treatment group were po administered with Compound Danshen Dripping Pills on the basis of the control group, 10 pills/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacies were evaluated, and revascularization rate and left heart function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.66% and 96.67%, respectively, and there was difference between two groups (P<0.05). After treatment, the revascularization rates in the control and treatment groups were 83.33% and 93.33%, respectively, and there was difference between two groups (P<0.05). After treatment, LVEDD and LVEF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the left heart function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Compound Danshen Dripping Pills combined with Reocmbinant Human Prourokinase for injection has clinical curative effect in treatment of acute ST segment elevation myocardial infarction, can significantly increase revascularization rate, and improve the left heart function, with good safety, which has a certain clinical application value.